Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Vittrup Diness

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancers|July 24, 2020
Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II TrialAlice Markussen, Lars Henrik Jensen, Laura Vittrup Diness, et al.
Acta Oncologica (Stockholm, Sweden)|April 17, 2026
Risk factors for distant recurrence in patients with rectal cancer supporting selection for total neoadjuvant therapyAnna Baech Slipsager, Rana Bahij, Heidi Søgaard Christensen, et al.
JAMA Surgery|March 4, 2026
Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical TrialLars Henrik Jensen, Monica Kjaer, Laura Vittrup Diness, et al.
The Lancet. Gastroenterology & Hepatology|May 1, 2026
Effect of one or two cycles of dual immunotherapy with nivolumab and ipilimumab in patients with mismatch repair-deficient rectal cancer (RESET-R): interim results from a multicentre, single-arm, phase 2 trialLine Schmidt Tarpgaard, Laurids Østergaard Poulsen, Ismail Gögenur, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancers|July 24, 2020
Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II TrialAlice Markussen, Lars Henrik Jensen, Laura Vittrup Diness, et al.
Acta Oncologica (Stockholm, Sweden)|April 17, 2026
Risk factors for distant recurrence in patients with rectal cancer supporting selection for total neoadjuvant therapyAnna Baech Slipsager, Rana Bahij, Heidi Søgaard Christensen, et al.
JAMA Surgery|March 4, 2026
Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical TrialLars Henrik Jensen, Monica Kjaer, Laura Vittrup Diness, et al.
The Lancet. Gastroenterology & Hepatology|May 1, 2026
Effect of one or two cycles of dual immunotherapy with nivolumab and ipilimumab in patients with mismatch repair-deficient rectal cancer (RESET-R): interim results from a multicentre, single-arm, phase 2 trialLine Schmidt Tarpgaard, Laurids Østergaard Poulsen, Ismail Gögenur, et al.
Pageof 1